| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA.
|
Drug Metab Pharmacokinet
|
2007
|
1.17
|
|
2
|
Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.
|
Biopharm Drug Dispos
|
2007
|
0.98
|
|
3
|
Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
|
Drug Metab Dispos
|
2010
|
0.95
|
|
4
|
Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
0.90
|
|
5
|
Identification of human metabolites of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites.
|
Drug Metab Dispos
|
2009
|
0.85
|
|
6
|
Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9.
|
Biopharm Drug Dispos
|
2004
|
0.83
|
|
7
|
Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.
|
Drug Metab Dispos
|
2004
|
0.83
|
|
8
|
Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
|
Drug Metab Dispos
|
2008
|
0.83
|
|
9
|
Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits.
|
J Ocul Pharmacol Ther
|
2008
|
0.82
|
|
10
|
Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
|
Drug Metab Dispos
|
2009
|
0.81
|
|
11
|
In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes.
|
Biopharm Drug Dispos
|
2005
|
0.80
|
|
12
|
In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid.
|
Biopharm Drug Dispos
|
2006
|
0.80
|
|
13
|
Absorption, distribution, and excretion of 14C-labeled tacrolimus (FK506) after a single or repeated ocular instillation in rabbits.
|
J Ocul Pharmacol Ther
|
2008
|
0.80
|
|
14
|
Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes.
|
Basic Clin Pharmacol Toxicol
|
2007
|
0.80
|
|
15
|
Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes.
|
Eur J Clin Pharmacol
|
2007
|
0.79
|
|
16
|
Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver.
|
Pharm Res
|
2006
|
0.79
|
|
17
|
Relationship between exposure of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a "funny" if current channel inhibitor, and heart rate reduction in tachycardia-induced beagle dogs.
|
Drug Metab Dispos
|
2009
|
0.79
|
|
18
|
The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver.
|
Drug Metab Dispos
|
2007
|
0.79
|
|
19
|
Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872).
|
Chem Pharm Bull (Tokyo)
|
2004
|
0.79
|
|
20
|
Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans.
|
Drug Metab Dispos
|
2008
|
0.79
|
|
21
|
Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.
|
Drug Metab Dispos
|
2008
|
0.77
|
|
22
|
Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB.
|
Biopharm Drug Dispos
|
2002
|
0.77
|
|
23
|
Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.
|
Drug Metab Dispos
|
2006
|
0.77
|
|
24
|
Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver.
|
Drug Metab Dispos
|
2007
|
0.77
|
|
25
|
The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.
|
Drug Metab Dispos
|
2006
|
0.77
|
|
26
|
Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver.
|
Eur J Clin Pharmacol
|
2007
|
0.77
|
|
27
|
In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans.
|
Biopharm Drug Dispos
|
2006
|
0.76
|
|
28
|
Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro.
|
Drug Metab Dispos
|
2009
|
0.76
|
|
29
|
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma.
|
Biomed Chromatogr
|
2008
|
0.76
|
|
30
|
Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes.
|
Drug Metab Dispos
|
2007
|
0.76
|
|
31
|
Simultaneous determination of YM928, a novel noncompetitive AMPA receptor antagonist, and its demethylated metabolite in rat, dog and monkey plasma by high-performance liquid chromatography with ultraviolet detection.
|
Biomed Chromatogr
|
2006
|
0.75
|
|
32
|
Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection.
|
Biomed Chromatogr
|
2004
|
0.75
|
|
33
|
LC determination of YM466, a new factor Xa inhibitor, in rat and dog plasma.
|
J Pharm Biomed Anal
|
2002
|
0.75
|
|
34
|
Pharmacokinetics of YM466, a new factor Xa inhibitor, in rats and dogs.
|
Eur J Drug Metab Pharmacokinet
|
2004
|
0.75
|
|
35
|
Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans.
|
J Pharm Sci
|
2008
|
0.75
|
|
36
|
Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide.
|
Biol Pharm Bull
|
2007
|
0.75
|
|
37
|
Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats.
|
Eur J Drug Metab Pharmacokinet
|
2006
|
0.75
|
|
38
|
A liquid chromatographic-tandem mass spectrometric method for the determination of YM466, a novel Factor Xa inhibitor, in rat plasma.
|
J Pharm Biomed Anal
|
2004
|
0.75
|
|
39
|
Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
|
Biopharm Drug Dispos
|
2004
|
0.75
|
|
40
|
Investigation of long-term retention of unchanged (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide, a novel "funny" If current channel inhibitor, and its metabolites in the eyeball and thoracic aorta of rats.
|
Drug Metab Dispos
|
2009
|
0.75
|